У нас вы можете посмотреть бесплатно The Critical Path Institute Podcast: Connecting the Dots with COA VP Dr. Cheryl Coon или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
The inaugural episode of the Critical Path Institute (C-Path) podcast serves as a platform to discuss the intersection of drug development, clinical science, and public health. Hosted by CEO Klaus Romero and guest Cheryl Coon, the episode explores how clinical outcome assessments (COAs) are essential in measuring patient experiences and determining drug efficacy. SUBSCRIBE to C-Path's YouTube Channel Now ►► / criticalpathinstitute FOLLOW C-Path: ►LinkedIn: / c-path ►Facebook: / cpathinstitute ►X: https://twitter.com/CPathInstitute?re ►Instagram: / cpathinstitute About Critical Path Institute C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org. #CPath #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch #regulatoryscience #globalhealth #consortia #collaboration #FDA #EMA #T1D #Parkinsons #Alzheimers #PKD #Duchenne #ALS #biomarkers